Yes, I did notice the new panel of experts. I must admit, I couldn't help thinking that OPT sure knows how to spend my money!
Interesting—where do you place the probabilities of success for the Phase 3 trials, specifically for COAST (Aflibercept/Eylea) and ShORe (Ranibizumab/Lucentis)? Then gaining approval by FDA?
Here’s what my OptheaGPT is saying (if anyone has any documents to link, I can add them to my OptheaGPT knowledge).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $738.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| OPT (ASX) Chart |
Day chart unavailable